var docs;if (!docs) docs =[]; docs["117"]={"11700":"<p><b>Title</b> Tacrolimus (Systemic) / Corticosteroids (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Genotype</b>: This interaction may be more clinically relevant in patients who express functional CYP3A5 compared with patients who have little CYP3A5 activity.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Consider monitoring for increased tacrolimus concentrations and effects more frequently when tapering or discontinuing systemic corticosteroids.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> In a randomized controlled trial of new kidney transplant recipients receiving tacrolimus and mycophenolate mofetil, patients who received prednisone for 3 months had tacrolimus dose-adjusted trough concentrations that were 30% lower than patients who received daclizumab without corticosteroid therapy.<sup>1</sup> After 3 months, patients in the prednisone-treated group had their prednisone discontinued. Compared with concentrations during the first month of the trial, tacrolimus dose-adjusted trough concentrations increased approximately 45% three months after prednisone discontinuation.<sup>1</sup> Other randomized controlled studies of corticosteroid withdrawal protocols in tacrolimus-treated transplant recipients have reported approximately a 20% increase in tacrolimus concentrations and a 40% increase in tacrolimus AUC after corticosteroid withdrawl.<sup>2,3</sup><br> <br>Retrospective analyses of transplant recipients have concluded that tacrolimus clearance is positively correlated (R=0.94) with corticosteroid dose.<sup>4</sup> After corticosteroid withdrawal, the tacrolimus AUC increased 20% and the dose-adjusted tacrolimus trough level increased 10% to 40%.<sup>5</sup> When compared with patients receiving corticosteroids, the tacrolimus AUC was 41% higher and the tacrolimus dose requirements were significantly lower in patients not taking corticosteroids.<sup>6,7</sup><br> <br>A retrospective study of 10 liver transplants recipients expressing CYP3A5 found that tacrolimus metabolite concentrations increased and tacrolimus serum concentrations decreased 27% after receiving high-dose corticosteroids for acute cellular rejection.<sup>8</sup> Tacrolimus concentrations were unchanged with high-dose corticosteroids in patients who did not express CYP3A5.<sup>8</sup> A large retrospective study of 450 renal transplant recipients reported that patients on lower corticosteroid doses were more likely to have lower tacrolimus requirements (odds ratio [OR], 3.101) and were less likely to express CYP3A5.<sup>9</sup><br><br>In contrast, a pharmacokinetic trial of 7 bone marrow transplant patients found that administration of high-dose methylprednisolone had no effect on the tacrolimus serum concentration or AUC.<sup>10</sup> A large retrospective analysis comparing tacrolimus dosage in African American and Caucasian patients concluded that corticosteroid dose did not affect tacrolimus dose requirements.<sup>11</sup><br><br>The mechanism for this interaction is unclear, but corticosteroids may induce CYP3A4 or CYP3A5, enzymes responsible for tacrolimus metabolism. Induction of CYP3A5 may be a more prominent mechanism, as this interaction was not observed in patients who lacked CYP3A5 activity.<sup>8</sup> Although tacrolimus concentrations are frequently monitored during routine tacrolimus use, additional monitoring may be appropriate when deciding to taper or discontinue corticosteroids, particularly in patients with CYP3A5 activity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. <i>Br J Clin Pharmacol</i>. 2003;56(3):327-330. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12919182\">[PubMed 12919182]</a></p>\n<p>2. Shihab FS, Lee ST, Smith LD, et al; M. R. First for the Astellas Corticosteroid Withdrawal Group. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. <i>Am J Transplant</i>. 2013;13(2):474-484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23167508\">[PubMed 23167508]</a></p>\n<p>3. Park SI, Felipe CR, Pinheiro-Machado PG, et al. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. <i>Fundam Clin Pharmacol</i>. 2009;23(1):137-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19267777\">[PubMed 19267777]</a></p>\n<p>4. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. <i>Transplant Proc</i>. 1998;30(4):1261-1263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9636512\">[PubMed 9636512]</a> 5. Van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. <i>Transpl Int</i>. 2003;16(10):721-725. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12827231\">[PubMed 12827231]</a></p>\n<p>6. Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti Vehaskari V. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. <i>Pediatr Transplant</i>. 2005;9(2):162-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15787787\">[PubMed 15787787]</a></p>\n<p>7. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. <i>Nephrol Dial Transplant</i>. 2003;18(11):2409-2414. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14551375\">[PubMed 14551375]</a></p>\n<p>8. Hosohata K, Uesugi M, Hashi S, et al. Association between CYP3A5 genotypes in graft liver and increase in tacrolimus biotransformation from steroid treatment in living-donor liver transplant patients. <i>Drug Metab Pharmacokinet</i>. 2014;29(1):83-89. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23955548\">[PubMed 23955548]</a></p>\n<p>9. Stratta P, Quaglia M, Cena T, et al. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. <i>Eur J Clin Pharmacol</i>. 2012;68(5):671-680. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22101623\">[PubMed 22101623]</a></p>\n<p>10. Boswell GW, Bekersky I, Fay J, et al. Tacrolimus pharmacokinetics in BMT patients. <i>Bone Marrow Transplant</i>. 1998;21(1):23-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9486490\">[PubMed 9486490]</a></p>\n<p>11. Laftavi MR, Pankewycz O, Patel S, et al. African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help? <i>Transplant Proc</i>. 2013;45(10):3498-3501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24314941\">[PubMed 24314941]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11701":"<p><b>Title</b> BusPIRone / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of BusPIRone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit the buspirone dose to 2.5 mg twice daily and monitor for increased buspirone effects/toxicities if combined with erythromycin.</p> \n<p><b>Discussion</b> A pharmacokinetic study of 8 healthy subjects given a 4-day course of erythromycin (500 mg three times daily) and a single dose of 10 mg of buspirone resulted in a 5-fold increase in the buspirone maximum plasma concentration (Cmax) and a 5.9-fold increase in buspirone AUC.<sup>1</sup> Subjects were noted to have impaired motor skills with the combination and all experienced buspirone side effects compared with none in the buspirone alone portion of the study.<sup>1</sup><br><br>Buspirone prescribing information states that coadministration with erythromycin may result in increased buspirone concentrations and recommends a maximum dose of buspirone 2.5 mg twice daily when used with erythromycin.<sup>2</sup><br> <br>The mechanism of this interaction is likely erythromycin-mediated inhibition of CYP3A4, an enzyme responsible for buspirone metabolism.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. <i>Clin Pharmacol Ther</i>. 1997;62(3):348-354. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9333111\">[PubMed 9333111]</a></p>\n<p>2. Buspar (buspirone) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11702":"<p><b>Title</b> BusPIRone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of BusPIRone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> A pharmacokinetic study of 8 healthy subjects given a 4 day course of itraconazole (100 mg two times daily) and a single dose of buspirone (10 mg) resulted in a 13.4-fold increase in the buspirone maximum plasma concentration (Cmax) and a 19.2-fold increase in the buspirone AUC.<sup>1</sup> This was associated with significant changes to visual acuity tests and all subjects experienced buspirone side effects during itraconazole coadministration.<sup>1</sup> In a pharmacokinetic study described in the buspirone prescribing information, nefazodone (250 mg twice daily) increased the buspirone (2.5 mg to 5 mg twice daily) Cmax and AUC 20-fold and 50-fold, respectively.<sup>2</sup> One case report describes a patient who experienced Parkinson-like symptoms after the addition of ritonavir/indinavir (a strong CYP 3A4 inhibitor) to chronic high dose buspirone (70 mg daily).<sup>3</sup><br><br>Buspirone prescribing information states that coadministration of itraconazole, nefazodone, and other strong CYP3A4 inhibitors may result in increased buspirone concentrations and toxicities.<sup>2</sup> A maximum dose of buspirone 2.5 mg daily is recommended when combined with strong CYP3A4 inhibitors.<sup>2</sup> <br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for buspirone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. <i>Clin Pharmacol Ther</i>. 1997;62(3):348-354. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9333111\">[PubMed 9333111]</a></p>\n<p>2. Buspar (buspirone) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2010.</p>\n<p>3. Clay PG, Adams MM. Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction. <i>Ann Pharmacother</i>. 2003;37(2):202-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12549947\">[PubMed 12549947]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11703":"<p><b>Title</b> Nefazodone / BusPIRone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> BusPIRone may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of BusPIRone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit the buspirone dose to 2.5 mg daily and monitor patients for increased buspirone effects/toxicities if combined with nefazodone. Additionally, monitor patient for signs of serotonin toxicity/serotonin syndrome (eg, confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia) if these agents are combined.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the buspirone prescribing information, nefazodone (250 mg twice daily) increased the buspirone (2.5 mg to 5 mg twice daily) maximum serum concentration and AUC 20-fold and 50-fold, respectively.<sup>1</sup><br><br>Buspirone prescribing information states that coadministration of nefazodone may result in increased buspirone concentrations and toxicities.<sup>1</sup> A maximum dose of buspirone 2.5 mg daily is recommended when combined with nefazodone.<sup>1</sup> Additionally, both nefazodone and buspirone have been associated with the development of serotonin syndrome; their combined use may lead to additive serotonergic effects and result in serotonin syndrome.<br><br>The mechanism of this pharmacokinetic interaction is likely due nefazodone-mediated inhibition of CYP3A4, an enzyme responsible for buspirone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Buspar (buspirone) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11704":"<p><b>Title</b> GlipiZIDE / Indobufen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Indobufen may increase the serum concentration of GlipiZIDE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased blood glucose concentrations during concomitant use of indobufen and glipizide.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy subjects, the glipizide AUC and maximum serum concentration (Cmax) were increased an average of 25% and 24%, respectively, when glipizide (single 5 mg dose) was administered before and at the conclusion of treatment with indobufen (200 mg for 1 dose then 200 mg twice daily for 5 days).<sup>1</sup> The product labeling for indobufen recommends frequent blood glucose monitoring when indobufen is administered with oral antidiabetic agents.<sup>2</sup> <br><br>The mechanism for this possible interaction is unknown, but it has been suggested that indobufen may inhibit glipizide metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Elvander-Stahl E, Melander A, Wahlin-Boll E. Indobufen interacts with the sulphonylurea, glipizide, but not with the beta-adrenergic receptor antagonists, propranolol and atenolol. <i>Br J Clin Pharmacol</i>. 1984;18(5):773-778. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6508985\">[PubMed 6508985]</a></p>\n<p>2. Ibustrin (indobufen) tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199400362 Accessed June 14, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11705":"<p><b>Title</b> Venlafaxine / Omeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Omeprazole may increase the serum concentration of Venlafaxine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A retrospective cohort study of venlafaxine-treated patients found that patients who received venlafaxine coadministered with omeprazole or pantoprazole (n = 80) had median plasma venlafaxine concentrations that were approximately 26% higher than patients who received venlafaxine alone (n = 906).<sup>1</sup> Additionally, median plasma concentrations of the active metabolite, O-desmethylvenlafaxine, were 36% higher in patients receiving venlafaxine with pantoprazole and 55% higher in patients receiving venlafaxine with omeprazole compared with patients who received venlafaxine alone.<sup>1</sup> Variation in sample timing, lack of control for potential confounders, and lack of correlation to clinical outcomes all limit general applicability of these study results.<br><br>The mechanism of this interaction has not been fully investigated, but omeprazole/pantoprazole-mediated inhibition of CYP2C19, an enzyme partially responsible for venlafaxine metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. <i>Clin Pharmacokinet</i>. Doi: 10.1007/s40262-017-0591-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28866861\">[PubMed 28866861]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11706":"<p><b>Title</b> Venlafaxine / Pantoprazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Pantoprazole may increase the serum concentration of Venlafaxine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A retrospective cohort study of venlafaxine-treated patients found that patients who received venlafaxine coadministered with omeprazole or pantoprazole (n = 80) had median plasma venlafaxine concentrations that were approximately 26% higher than patients who received venlafaxine alone (n = 906).<sup>1</sup> Additionally, median plasma concentrations of the active metabolite, O-desmethylvenlafaxine, were 36% higher in patients receiving venlafaxine with pantoprazole and 55% higher in patients receiving venlafaxine with omeprazole compared with patients who received venlafaxine alone.<sup>1</sup> Variation in sample timing, lack of control for potential confounders, and lack of correlation to clinical outcomes all limit general applicability of these study results.<br><br>The mechanism of this interaction has not been fully investigated, but omeprazole/pantoprazole-mediated inhibition of CYP2C19, an enzyme partially responsible for venlafaxine metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kuzin M, Schoretsanitis G, Haen E, et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine [published online September 2, 2017]. <i>Clin Pharmacokinet</i>. doi: 10.1007/s40262-017-0591-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28866861\">[PubMed 28866861]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11707":"<p><b>Title</b> Sirolimus / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider avoiding concurrent use of sirolimus with strong CYP3A4 inhibitors in order to minimize the risk for sirolimus toxicity. Concomitant use of sirolimus and voriconazole or posaconazole is listed as a contraindication in product labeling. Preemptive sirolimus dose reductions of 50% to 90% have been suggested when combined with various strong CYP3A4 inhibitors. Please review applicable labeling. Monitor for increased sirolimus concentrations/toxicity during concomitant use.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Several studies have evaluated the effect of strong CYP3A4 inhibitors on the pharmacokinetics of sirolimus. The AUC of sirolimus increased 4.5- to 11-fold when combined with voriconazole,<sup>1,2</sup> 9.9- to 10.9 fold with ketoconazole,<sup>1,3,4</sup> 1.6-fold with nelfinavir,<sup>5</sup> 8.9-fold with posaconazole,<sup>6,7</sup> and 26.1-fold with telaprevir.<sup>8</sup> The maximum serum concentration of sirolimus increased 3.1- to 7-fold when combined with these strong CYP3A4 inhibitors.<sup>1,2,3,4,5,6,7,8</sup> Additionally, the coadministration of sirolimus with strong CYP3A4 inhibitors may result in adverse effects and/or decreased sirolimus dose requirements.<sup>2,9,10</sup><br><br>Numerous studies have attempted to determine how to manage these drug interactions. When combined specifically with ketoconazole, posaconazole, voriconazole, and telaprevir, dose reductions of 50% to 90% have been recommended.<sup>9,11,12,13,14,15,16,17</sup><br><br>Although the sirolimus prescribing information recommends avoiding concomitant use of sirolimus with strong CYP3A4 inhibitors, the voriconazole and posaconazole prescribing information define this as a contraindicated drug combination.<sup>1,18,19</sup> <br><br>The likely mechanism of this interaction is inhibition of the CYP3A4-mediated metabolism of sirolimus. Inhibition of P-glycoprotein, a transporter involved in sirolimus distribution, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vfend (voriconazole) [prescribing information]. New York City, NY: Pfizer Inc; February 2015.</p>\n<p>2. Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. <i>Transplant Proc</i>. 2004;36(10):3226-3228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15686733\">[PubMed 15686733]</a> </p>\n<p>3. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. <i>AAPS J</i>. 2004;6(4):e28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15760093\">[PubMed 15760093]</a></p>\n<p>4. Cohen EE, Wu K, Hartford C, et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. <i>Clin Cancer Res</i>. 2012;18(17):4785-4793. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22872575\">[PubMed 22872575]</a></p>\n<p>5. Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. <i>Liver Transpl</i>. 2002;8(9):838-840. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12200787\">[PubMed 12200787]</a></p>\n<p>6. Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. <i>Curr Med Res Opin</i>. 2009;25(3):701-707. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19196220\">[PubMed 19196220]</a></p>\n<p>7. Greco R, Barbanti MC, Lupo Stranghellini MT, et al. Coadministration of posaconazole and sirolimus in allogenic hepatopoietic stem cell transplant recipients. <i>Bone Marrow Transplant</i>. 2016;51(7):1022-1024. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27111047\">[PubMed 27111047]</a></p>\n<p>8. O'Leary JG, McKenna GJ, Klintmalm G, Davis GL. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. <i>Liver Transpl</i>. 2013;19(4):463-465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23408534\">[PubMed 23408534]</a></p>\n<p>9. Ceberio I, Dai K, Devlin SM, et al. Safety of voriconazole and sirolimus coadministration after allogeneic hepatopoietic SCT. <i>Bone Marrow Transplant</i>. 2015;50(3):438-443. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25599164\">[PubMed 25599164]</a></p>\n<p>10. Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. <i>Transplantation</i>. 2004;77(3):474-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14966432\">[PubMed 14966432]</a></p>\n<p>11. Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. <i>Transplant Proc</i>. 2004;36(9):2708-2709. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15621130\">[PubMed 15621130]</a></p>\n<p>12. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. <i>Biol Blood Marrow Transplant</i>. 2006;12(5):552-559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16635790\">[PubMed 16635790]</a></p>\n<p>13. Greco R, Barbanti MC, Lupo Stranghellini MT, et al. Coadministration of posaconazole and sirolimus in allogenic hepatopoietic stem cell transplant recipients. <i>Bone Marrow Transplant</i>. 2016;51(7):1022-1024. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27111047\">[PubMed 27111047]</a></p>\n<p>14. Cho E, Chan H, Nguyen HM, Shayani S, Nakamura R, Pon D. Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant. <i>Pharmacotherapy</i>. 2015;35(6):578-585. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26037821\">[PubMed 26037821]</a></p>\n<p>15. Kubiak DW, Koo S, Hammond SP, Armand P, et al. Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. <i>Biol Blood Marrow Transplant</i>. 2012;18(9):1462-1465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22564264\">[PubMed 22564264]</a></p>\n<p>16. Peksa GD, Schultz K, Fung HC. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. <i>J Oncol Pharm Pract</i>. 2015;21(6):409-415. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24938293\">[PubMed 24938293]</a></p>\n<p>17. Werner CR, Egetemeyr DP, Lauer UM, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. <i>Liver Transpl</i>. 2012;18(12):1464-1470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22941516\">[PubMed 22941516]</a></p>\n<p>18. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; April 2017.</p>\n<p>19. Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11708":"<p><b>Title</b> Sirolimus / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of Sirolimus. Sirolimus may increase the serum concentration of Erythromycin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of sirolimus and erythromycin is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the sirolimus prescribing information, coadministration of erythromycin (800 mg every 8 hours) and sirolimus (2 mg daily) increased the sirolimus AUC and maximum serum concentration (Cmax) 4.2-fold and 4.4-fold, respectively.<sup>1</sup> The AUC and Cmax of erythromycin increased 1.7-fold and 1.6-fold, respectively.<sup>1</sup> Additionally, a case series describes 2 patients on long-term sirolimus who experienced 5-fold increases in sirolimus serum concentrations after the addition of erythromycin therapy, despite sirolimus dose reductions.<sup>2</sup><br><br>Sirolimus prescribing information states that because erythromycin may increases concentrations of sirolimus, the concomitant use of erythromycin and sirolimus is not recommended.<sup>1</sup><br><br>The mechanism of this interaction is likely erythromycin-mediated inhibition of CYP3A4 and P-glycoprotein, an enzyme and transporter responsible for sirolimus metabolism and distribution.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; April 2017.</p>\n<p>2. Claesson K, Brattstrom C, Burke JT. Sirolimus and erythromycin interaction: two cases. <i>Transplant Proc</i>. 2001;33(3):2136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11377477\">[PubMed 11377477]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11709":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents / Acemetacin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Acemetacin may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The use of acemetacin with other nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The labeling for acemetacin states that concurrent use with other NSAIDs should be avoided, and this includes both non-selective and COX-2-selective agents.<sup>1</sup><br><br>The likely reason for this recommendation is concern about a potential for increased NSAID-related adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Emflex (acemetacin) [UK summary of product characteristics]. Feltham, Middlesex, United Kingdom: Merck Serono Ltd; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11710":"<p><b>Title</b> Zidovudine / Acemetacin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acemetacin may enhance the adverse/toxic effect of Zidovudine. Specifically, the risk for hematologic toxicity may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of hematologic toxicity in patients using this combination.</p> \n<p><b>Discussion</b> The acemetacin summary of product characteristics states that concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs) with zidovudine may be associated with hematologic toxicity.<sup>1</sup> The only details included in the labeling is a reference to an increased risk of hemarthrosis and hematoma in HIV-positive patients with hemophilia who received both ibuprofen (an NSAID) and zidovudine.<br><br>Though no published studies specifically address a possible risk for anemia or other red blood cell toxicities with this combination, there is evidence that several NSAIDs, such as dexketoprofen, may impair zidovudine metabolism and/or transport and may increase intracellular zidovudine concentrations from both clinical studies<sup>2</sup> and animal studies.<sup>3,4,5,6</sup> In contrast, other clinical and animal studies have reported no significant change in zidovudine pharmacokinetics with concurrent administration of NSAIDs.<sup>7,8,9</sup><br><br>The specific mechanism for any possible interaction is uncertain, but NSAID inhibition of zidovudine glucuronidation and/or efflux via multidrug resistance protein 4 (MRP4) are possible explanations.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Emflex (acemetacin) [UK summary of product characteristics]. Feltham, Middlesex, United Kingdom: Merck Serono Ltd; May 2016.</p>\n<p>2. Barry M, Howe J, Back D, et al. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. <i>Br J Clin Pharmacol</i>. 1993;36(1):82-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8373716\">[PubMed 8373716]</a></p>\n<p>3. Clemente MI, Alvarez S, Serramia MJ, et al. Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4. <i>Antivir Ther</i>. 2009;14(8):1101-1111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20032540\">[PubMed 20032540]</a></p>\n<p>4. Mano Y, Usui T, Kamimura H. Comparison of inhibition potentials of drugs against zidovudine glucuronidation in rat hepatocytes and liver microsomes. <i>Drug Metab Dispos</i>. 2007;35(4):602-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267620\">[PubMed 17267620]</a></p>\n<p>5. Mano Y, Usui T, Kamimura H. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. <i>Eur J Clin Pharmacol</i>. 2007;63(2):211-216. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17200831\">[PubMed 17200831]</a></p>\n<p>6. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. <i>Br J Clin Pharmacol</i>. 1991;32(1):17-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1909542\">[PubMed 1909542]</a></p>\n<p>7. Sahai J, Gallicano K, Garber G, et al. Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. <i>Clin Pharmacol Ther</i>. 1992;52(5):464-470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1424420\">[PubMed 1424420]</a></p>\n<p>8. Ragni MV, Miller BJ, Whalen R, Ptachcinski R. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. <i>Am J Hematol</i>. 1992;40(3):176-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1609771\">[PubMed 1609771]</a></p>\n<p>9. Radwan MA. Zidovudine, diclofenac and ketoprofen pharmacokinetic interactions in rats. <i>J Pharm Pharmacol</i>. 2000;52(6):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10875543\">[PubMed 10875543]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11711":"<p><b>Title</b> Fosphenytoin-Phenytoin / Acemetacin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acemetacin may increase the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of phenytoin adverse effects or other evidence of increased phenytoin exposure.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> The acemetacin labeling states that phenytoin elimination may be reduced by concurrent use of acemetacin.<sup>1</sup> No evidence is included with or cited by the labeling.<br><br>The mechanism by which acemetacin, or other NSAIDs, would reduce phenytoin elimination is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Emflex (acemetacin) [UK summary of product characteristics]. Feltham, Middlesex, United Kingdom: Merck Serono Ltd; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11712":"<p><b>Title</b> Penicillins / Acemetacin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acemetacin may increase the serum concentration of Penicillins. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of penicillin adverse effects or other evidence of increased exposure to the penicillin.</p>\n<div>\n <p><b>Penicillins Interacting Members</b> Amdinocillin, Amoxicillin, Ampicillin, Bacampicillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Nafcillin, Oxacillin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Piperacillin, Temocillin, Ticarcillin</p>\n</div> \n<p><b>Discussion</b> The acemetacin labeling states that the elimination of penicillins may be reduced by concurrent use of acemetacin.<sup>1</sup> No evidence is included with or cited by the labeling.<br><br>The mechanism by which acemetacin, or other NSAIDs, would reduce penicillin elimination is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Emflex (acemetacin) [UK summary of product characteristics]. Feltham, Middlesex, United Kingdom: Merck Serono Ltd; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11727":"<p><b>Title</b> Bosentan / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Bosentan. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 16 healthy volunteers, grapefruit juice (300 mL 3 times daily x 1 day) had no effect on the bosentan (125 mg twice daily x 2 doses) AUC or maximum serum concentration.<sup>1</sup><br><br>Bosentan prescribing information recommends caution when combining bosentan with moderate CYP3A4 inhibitors (eg, grapefruit juice).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Markert C, Wirsching T, Hellwig R, et al. Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults. <i>Int J Clin Pharmacol Ther</i>. 2014;52(11):957-964. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25207548\">[PubMed 25207548]</a></p>\n<p>2. Tracleer (bosentan) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11728":"<p><b>Title</b> Budesonide (Topical) / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Budesonide (Topical). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid grapefruit juice consumption with the use of topical budesonide.</p> \n<p><b>Discussion</b> Clinical studies investigating the concurrent administration of rectal (topical) budesonide and grapefruit juice are not available. However, administration of oral budesonide with grapefruit juice resulted in an approximately 2-fold increase in budesonide exposure.<sup>1</sup><br><br>Prescribing information for topical budesonide recommends avoiding concomitant use with grapefruit juice.<sup>1</sup><br><br>The mechanism of this interaction is likely due to grapefruit juice-mediated inhibition of intestinal CYP3A4, an enzyme responsible for the metabolism of budesonide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Uceris (budesonide) rectal foam [prescribing information]. Raleigh, NC: Salix Pharmaceuticals Inc; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11729":"<p><b>Title</b> FentaNYL / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of FentaNYL. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of grapefruit juice (250 mL of regular strength the evening before, followed by 100 mL of double strength the following morning) and oral transmucosal fentanyl lozenge (10 mcg/kg given 1 hour after grapefruit juice) had no effect on the maximum serum concentration, AUC, or clearance of fentanyl.<sup>1</sup><br><br>Fentanyl prescribing information states that CYP3A4 inhibitors, including grapefruit juice, can increase the plasma concentration of fentanyl, resulting in increased or prolonged opioid effects.<sup>2</sup> Grapefruit juice is typically considered a moderate CYP3A4 inhibitor, but because it only inhibits intestinal CYP3A4 and has little effect on hepatic CYP3A4, it is unlikely to affect concentrations of fentanyl, a drug that is administered via-non-oral routes (ie, intravenous, transmucosal, transdermal, intranasal, sublingual).<sup>3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. <i>Anesthesiology</i>. 2004;101(3):729-737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15329598\">[PubMed 15329598]</a></p>\n<p>2. Actiq (fentanyl citrate) oral transmucosal lozenge [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; December 2016.</p>\n<p>3. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. <i>Eur J Clin Pharmacol</i>. 1997;52(2):139-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9174684\">[PubMed 9174684]</a></p>\n<p>4. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. <i>Clin Pharmacol Ther</i>. 1995;58(1):20-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7628179\">[PubMed 7628179]</a></p>\n<p>5. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. <i>J Clin Invest</i>. 1997;99(10):2545-2553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9153299\">[PubMed 9153299]</a></p>\n<p>6. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. <i>Clin Pharmacol Ther</i>. 2003;74(2):121-129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12891222\">[PubMed 12891222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11730":"<p><b>Title</b> Colchicine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Colchicine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid consumption of grapefruit juice while taking colchicine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 healthy subjects, coadministration of grapefruit juice (240 mL twice daily x 4 days) and colchicine (0.6 mg x 1 dose) did not affect the maximum plasma concentration or AUC of colchicine, although the time to maximum concentration was slightly prolonged from 1 to 1.5 hours.<sup>1</sup> A case report describes an 8-year-old girl with familial Mediterranean fever who experienced a near fatal colchicine intoxication with the concomitant administration of colchicine (2 mg daily for 10 months) and grapefruit juice (1 liter daily for 2 months).<sup>2</sup><br><br>Colchicine prescribing information states that because grapefruit juice may increase colchicine concentrations, it should not be consumed during colchicine treatment.<sup>3</sup> <br><br>The mechanism of this interaction is likely grapefruit juice-mediated inhibition of intestinal CYP3A4, an enzyme responsible for colchicine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wason S, DiGiancinto JL, Davis MW. Effects of grapefruit juice and Seville orange juice on the pharmacokinetic properties of colchicine in healthy subjects. <i>Clin Ther</i>. 2012;34(10):2161-2173. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22940371\">[PubMed 22940371]</a> </p>\n<p>2. Goldbart A, Press J, Sofer S, Kapelushnik J. Near fatal acute colchicine intoxication in a child. A case report. <i>Eur J Pediatr</i>. 2000;159(12):895-897. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11131346\">[PubMed 11131346]</a></p>\n<p>3. Colcrys (colchicine) [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11731":"<p><b>Title</b> Deflazacort / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Deflazacort. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of deflazacort and grapefruit juice. Although the deflazacort oral suspension may be given with other juices, it should not be given with grapefruit juice.</p> \n<p><b>Discussion</b> According to the deflazacort prescribing information, exposure to the active deflazacort metabolite, 21-desDFZ, was increased by approximately 3-fold with concurrent use of clarithromycin, a strong CYP3A4 inhibitor and inhibitor of p-glycoprotein.<sup>1</sup> Although the combined use of deflazacort and grapefruit juice have not been evaluated in a clinical study, grapefruit juice is a moderate CYP3A4 inhibitor and would be expected to increase deflazacort exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Emflaza (deflazacort) [prescribing information]. Northbrook, IL: Marathon Pharmaceuticals, LLC; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11732":"<p><b>Title</b> Ifosfamide / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Grapefruit Juice may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 8 patients with malignancies that were considered incurable, coadministration of the strong CYP3A inhibitor ketoconazole (200 mg orally twice daily for 4 days, beginning 1 day before ifosfamide) increased ifosfamide (3 g/m2 intravenously over 24 hours) AUC by 14%, increased AUC of its 2-dechloroethylifosfamide metabolite by 23%, and decreased AUCs of the metabolites 3-dechloroethylifosfamide and 4-hydroxyifosfamide by 6% and 30%, respectively.<sup>1</sup> Of these findings, only the increase in 2-dechloroethylifosfamide AUC was statistically significant.<br><br>The ifosfamide prescribing information states that concomitant use of ifosfamide with CYP3A4 inhibitors may decrease the metabolism of ifosfamide to its active alkylating metabolites,<br>perhaps decreasing the effectiveness of ifosfamide treatment.<sup>2</sup> Although ifosfamide prescribing information lists grapefruit juice as a clinically relevant CYP3A4 inhibitor, the majority of the clinical data suggest that grapefruit juice only inhibits intestinal CYP3A4 but has little effect on hepatic CYP3A4.<sup>3,4,5,6</sup> Therefore, it is unlikely to affect concentrations of ifosfamide, a drug that is administered intravenously.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kerbusch T, Jansen RL, Mathot RA, et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. <i>Clin Pharmacol Ther</i>. 2001;70(2):132-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503007\">[PubMed 11503007]</a></p>\n<p>2. Ifex (ifosfamide) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; August 2014.</p>\n<p>3. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. <i>Eur J Clin Pharmacol</i>. 1997;52(2):139-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9174684\">[PubMed 9174684]</a></p>\n<p>4. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. <i>Clin Pharmacol Ther</i>. 1995;58(1):20-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7628179\">[PubMed 7628179]</a></p>\n<p>5. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. <i>J Clin Invest</i>. 1997;99(10):2545-2553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9153299\">[PubMed 9153299]</a></p>\n<p>6. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. <i>Clin Pharmacol Ther</i>. 2003;74(2):121-129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12891222\">[PubMed 12891222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11733":"<p><b>Title</b> Tamsulosin / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased tamsulosin effects (eg, hypotension, orthostasis) if tamsulosin is combined with a moderate CYP3A4 inhibitor. Increases in tamsulosin exposure may be greater if a CYP3A4 inhibitor and a CYP2D6 inhibitor are combined with tamsulosin.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 24 healthy subjects, administration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 5 days) increased tamsulosin (0.4 mg single dose given on day 4) AUC and maximum serum concentration 2.8-fold and 2.2-fold, respectively.<sup>1,2,3</sup> No changes in blood pressure or heart rate were noted.<sup>3</sup><br><br>Prescribing information for tamsulosin products states that tamsulosin and moderate CYP3A4 inhibitors should be combined with caution and patients should be monitored for increased tamsulosin effects.<sup>2</sup> Although never evaluated in a clinical study, prescribing information also states that increases in tamsulosin exposure may be greater if a CYP3A4 inhibitor and a CYP2D6 inhibitor are combined with tamsulosin.<sup>1,2</sup><br><br>The mechanism of this potential interaction is that CYP2D6 and CYP3A4 are responsible for a significant portion of tamsulosin metabolism. The inhibition of CYP3A4 by moderate inhibitors may lead to increased tamsulosin exposure and effects.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Flomax (tamsulosin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; October 2014.</p>\n<p>2. Jalyn (dutasteride and tamsulosin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</p>\n<p>3. Troost J, Tatami S, Tsuda Y, et al. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. <i>Br J Clin Pharmacol</i>. 2011;72(2):247-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21496064\">[PubMed 21496064]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11734":"<p><b>Title</b> Tamsulosin / CYP2D6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased tamsulosin effects (eg, hypotension, orthostasis) if tamsulosin is combined with a moderate CYP2D6 inhibitor. Increases in tamsulosin exposure may be greater if a CYP2D6 inhibitor and a CYP3A4 inhibitor are combined with tamsulosin.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 24 healthy volunteers, the strong CYP2D6 inhibitor paroxetine (10 mg daily for 3 days, then 20 mg daily for 9 days) increased the tamsulosin (0.4 mg single dose given on day 11) AUC and maximum serum concentration 1.6-fold and 1.3-fold, respectively.<sup>1,2,3</sup> No changes in blood pressure or heart rate were seen.<sup>3</sup> <br><br>Prescribing information for tamsulosin products states that tamsulosin and moderate CYP2D6 inhibitors should be combined with caution and patients should be monitored for increased tamsulosin effects.<sup>2</sup> Although never evaluated in a clinical study, prescribing information also states that increases in tamsulosin exposure may be greater if a CYP2D6 inhibitor and a CYP3A4 inhibitor are combined with tamsulosin.<sup>1,2</sup><br><br>The mechanism of this potential interaction is that CYP2D6 and CYP3A4 are responsible for a significant portion of tamsulosin metabolism. The inhibition of CYP2D6 by moderate inhibitors may lead to increased tamsulosin exposure and effects.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Flomax (tamsulosin) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; October 2014.</p>\n<p>2. Jalyn (dutasteride and tamsulosin) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</p>\n<p>3. Troost J, Tatami S, Tsuda Y, et al. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. <i>Br J Clin Pharmacol</i>. 2011;72(2):247-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21496064\">[PubMed 21496064]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11735":"<p><b>Title</b> Lincomycin / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Erythromycin (Systemic) may diminish the therapeutic effect of Lincomycin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of erythromycin and lincomycin.</p> \n<p><b>Discussion</b> In vitro studies have demonstrated antagonism between erythromycin and lincomycin whereby strains of <i>Staphylococcus</i> spp. and <i>Streptococcus pyogenes</i> that are resistant to erythromycin rapidly display resistance to lincomycin when exposed to both erythromycin and lincomycin.<sup>1,2</sup> The prescribing information for lincomycin states that because of this antagonism, the combination of lincomycin and erythromycin should be avoided.<sup>3</sup><br><br>The specific mechanism of this apparent antagonism is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Griffith LJ, Ostrander WE, Mullins CG, Beswick DE. Drug antagonism between lincomycin and erythromycin. <i>Science</i>. 1965;147(3659):746-747. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14242023\">[PubMed 14242023]</a></p>\n<p>2. Annear DI. Interaction between erythromycin and lincomycin in Streptococcus pyogenes. <i>J Med Microbiol</i>. 1978;11(2):193-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=351184\">[PubMed 351184]</a></p>\n<p>3. Lincocin (lincomycin) [prescribing information]. Kalamazoo, MI: Pharmacia and Upjohn Company; June 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11736":"<p><b>Title</b> Grapefruit Juice / Telithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Telithromycin does not appear to affect serum concentration of Grapefruit Juice. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 16 healthy patients, grapefruit juice (240 mL single dose) had no effect on the telithromycin (800 mg single dose) pharmacokinetic parameters.<sup>1</sup><br> <br>Telithromycin prescribing information states that coadministration of telithromycin with CYP3A4 inhibitors can result in increased plasma levels, but specifically states that grapefruit juice will have no impact.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Shi J, Montay G, Leroy B, Bhargava VO. Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. <i>Pharmacotherapy</i>. 2005;25(1):42-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15767219\">[PubMed 15767219]</a></p>\n<p>2. Ketek (telithromycin) [prescribing information]. Bridgewater, NJ; Sanof-Aventis US LLC; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11737":"<p><b>Title</b> Pidotimod / Immunosuppressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Immunosuppressants may diminish the therapeutic effect of Pidotimod. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to pidotimod closely when using immunosuppressants concomitantly.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Cytarabine (Liposomal), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> The pidotimod product labeling cautions that pidotimod may interact with immunosuppressant drugs.<sup>1</sup> Though specific data regarding this potential interaction are not available, based on the immune-stimulating activity of pidotimod, it is possible that concurrent use of drugs that suppress the immune system may interfere with the clinical activity of pidotimod.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pidotimod [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199800941. Accessed October 31, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11738":"<p><b>Title</b> Sildenafil / Grapefruit Juice</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to orally administered sildenafil.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Sildenafil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased sildenafil effects/toxicities if combined with grapefruit juice.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 24 healthy males, grapefruit juice (250 mL) given before and with sildenafil (50 mg single dose) increased the sildenafil AUC 23% but did not change the maximum serum concentration (Cmax).<sup>1</sup> In a single person pharmacokinetic analysis, grapefruit juice (250 mL) increased the sildenafil (25 mg single dose) AUC and Cmax 168% and 35%, respectively.<sup>2</sup> In another single person pharmacokinetic analysis, grapefruit juice (250 mL) increased the sildenafil (100 mg single dose) Cmax 42%, but had no effect on the sildenafil AUC.<sup>3</sup><br><br>The mechanism of this interaction appears to be grapefruit juice mediated inhibition of intestinal CYP3A4, an enzyme responsible for sildenafil metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. <i>Clin Pharmacol Ther</i>. 2002;71(1):21-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11823754\">[PubMed 11823754]</a></p>\n<p>2. Sheu MT, Wu AB, Yeh GC, Hsia A, Ho HO. Development of a liquid chromatographic method for bioanalytical applications with sildenafil. <i>J Chromatogr B Analyt Technol Biomed Life Sci</i>. 2003;791(1-2):255-262. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12798185\">[PubMed 12798185]</a></p>\n<p>3. Lee M, Min DI. Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. <i>Ther Drug Monit</i>. 2001;23(1):21-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11206038\">[PubMed 11206038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11739":"<p><b>Title</b> Acalabrutinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Acalabrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid co-administration of strong CYP3A inducers in patients taking acalabrutinib. If strong CYP3A inducers cannot be avoided, increase the dose of acalabrutinib to 200 mg twice daily.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Acalabrutinib maximum serum concentration (Cmax) and AUC were reduced by 68% and 77%, respectively, in healthy subjects when given concurrently with the strong CYP3A inducer rifampin (600 mg once daily for 9 days).<sup>1</sup><br><br>The likely mechanism for this interaction is increased CYP3A-mediated metabolism acalabrutinib by strong CYP3A inducers such as rifampin, leading to reduced acalabrutinib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Calquence (acalabrutinib) [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11740":"<p><b>Title</b> Acalabrutinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Acalabrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid co-administration of strong CYP3A inhibitors in patients taking acalabrutinib. If the strong CYP3A inhibitor is to be used short-term (eg, anti-infective for up to seven days), it is recommended to interrupt acalabrutinib therapy.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Acalabrutinib maximum serum concentration (Cmax) and AUC were increased by 3.9- and 5.1-fold, respectively, in healthy subjects receiving the strong CYP3A inhibitor itraconazole 200 mg once daily for 5 days.<sup>1</sup><br><br>The likely mechanism for this apparent interaction is diminished CYP3A activity caused by the strong CYP3A inhibitors such as itraconazole leading to decreased CYP3A-mediated acalabrutinib metabolism and increased acalabrutinib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Calquence (acalabrutinib) [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11741":"<p><b>Title</b> Acalabrutinib / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> The acalabrutinib maximum serum concentration (Cmax) and AUC are predicted to increase by approximately 2- to less than 3-fold when co-administered with a moderate CYP3A inhibitor according to the results of a physiologically based pharmacokinetic simulation described in the acalabrutinib prescribing information.<sup>1</sup><br><br>The mechanism of this predicted interaction is decreased CYP3A-mediated metabolism of acalabrutinib caused by a moderate CYP3A inhibitor, resulting in increased acalabrutinib concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Calquence (acalabrutinib) [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11742":"<p><b>Title</b> Acalabrutinib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Acalabrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of acalabrutinib with any proton pump inhibitor (PPI). Due to the long half-life of the PPIs, separating administration of these agents is not likely to eliminate the interaction.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The acalabrutinib AUC was decreased by 53% when co-administered with the antacid calcium carbonate (1 g), and the acalabrutinib AUC was decreased by 43% when co-administered with the PPI omeprazole (40 mg for 5 days) according to studies of healthy subjects. Such decreases in acalabrutinib concentrations may reduce acalabrutinib activity, so the acalabrutinib labeling recommends that if treatment with a gastric acid reducing agent is required, a histamine-2 receptor antagonist (H2RA) or an antacid should be considered, with separation of administration to minimize the likelihood of a significant interaction.<sup>1</sup><br><br>Other gastric acid suppressants have avoided this interaction by separating the dosing between the two groups. However, with the long-lasting effect of PPIs, separation of doses may not eliminate the interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Calquence (acalabrutinib) [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11743":"<p><b>Title</b> Acalabrutinib / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> To minimize the potential for a significant interaction, separate administration of these agents by giving acalabrutinib 2 hours before ingestion of a histamine-2 receptor antagonist (H2RA).</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> The acalabrutinib AUC was decreased by 53% when co-administered with the antacid calcium carbonate (1 g), and the acalabrutinib AUC was decreased by 43% when co-administered with the proton pump inhibitor omeprazole (40 mg for 5 days) according to studies of healthy subjects. Such decreases in acalabrutinib concentrations may reduce acalabrutinib activity, so the acalabrutinib labeling recommends that if treatment with a gastric acid reducing agent is required, a H2RA or an antacid should be considered, with separation of administration to minimize the likelihood of a significant interaction.<sup>1</sup><br><br>The mechanism of this apparent interaction is likely reduced acalabrutinib solubility due to increased gastric pH caused by the gastric acid suppressant. With a half-life around 12 hours, H2RAs can avoid this interaction by taking acalabrutinib 2 hours before the acid suppressant.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Calquence (acalabrutinib) [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11744":"<p><b>Title</b> Acalabrutinib / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Acalabrutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Separate administration of acalabrutinib from the administration of any antacids by at least 2 hours in order to minimize the potential for a significant interaction.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The acalabrutinib AUC was decreased by 53% when co-administered with the antacid calcium carbonate (1 g), and the acalabrutinib AUC was decreased by 43% when co-administered with the proton pump inhibitor (PPI) omeprazole (40 mg for 5 days) according to studies of healthy subjects. Such decreases in acalabrutinib concentrations may reduce acalabrutinib activity, so the acalabrutinib labeling recommends that if treatment with a gastric acid reducing agent is required, a histamine-2 receptor antagonist (H2RA) or an antacid should be considered, with separation of administration to minimize the likelihood of a significant interaction.<sup>1</sup><br><br>Due to a short half-life compared to other gastric acid suppressants, antacids can be taken 2 hours before or after dosing of acalabrutinib, unlike H2RAs or PPIs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Calquence (acalabrutinib) [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11745":"<p><b>Title</b> Letermovir / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Letermovir. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Decrease the letermovir dose to 240 mg daily when combined with cyclosporine. Additionally, monitor for increased cyclosporine concentrations and toxicities when combined with letermovir.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, cyclosporine (50 mg single dose) increased the letermovir (40 mg twice daily) AUC and maximum serum concentration (Cmax) 126% and 109%, respectively.<sup>1</sup> A higher dose of cyclosporine (200 mg single dose) increased the letermovir AUC and Cmax 237% and 167%, respectively.<sup>1</sup> In a separate pharmacokinetic analysis, low-dose letermovir (80 mg twice daily) increased the cyclosporine (50 mg single dose) AUC and Cmax 76% and 37%, respectively.<sup>1</sup> In pharmacokinetic studies described in the letermovir prescribing information, cyclosporine (200 mg single dose) increased the letermovir (240 mg daily) AUC and Cmax 311% and 148%, respectively, and letermovir (240 mg daily) increased the cyclosporine (50 mg single dose) AUC 266%.<sup>2</sup><br><br>The letermovir prescribing information states that because cyclosporine can increase letermovir concentrations, the letermovir dose should be reduced to 240 mg daily when combined with cyclosporine.<sup>1</sup> Additionally, because letermovir can increase cyclosporine concentrations, increased monitoring for elevated cyclosporine concentrations and toxicities should occur when these agents are combined.<sup>2</sup><br><br>The mechanism by which cyclosporine increases letermovir concentrations is likely due to cyclosporine-mediated inhibition of OATP1B1/1B3, transporters responsible for letermovir hepatic uptake. The mechanism by which letermovir increases cyclosporine concentrations is likely due to letermovir-mediated inhibition of CYP3A4, an enzyme responsible for cyclosporine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kropeit D, von Richter O, Stobernack HP, Rubsamen-Schaeff H, Zimmermann H. Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects [published online October 2, 2017]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28967706\">[PubMed 28967706]</a></p>\n<p>2. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11746":"<p><b>Title</b> Tacrolimus (Systemic) / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased tacrolimus concentrations and effects if combined with letermovir. Tacrolimus dose reductions may be required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteer, low-dose letermovir (80 mg twice daily) increased the tacrolimus (5 mg single dose) AUC and maximum serum concentration (Cmax) 78% and 70%, respectively.<sup>1</sup> In a pharmacokinetic study described in the letermovir prescribing information, letermovir (480 mg daily) increased the tacrolimus (5 mg single dose) AUC, Cmax, and trough concentrations 342%, 257%, and 353%, respectively.<sup>2</sup><br><br>The letermovir prescribing information states that because letermovir can increase tacrolimus concentrations, clinicians should frequently monitor tacrolimus concentrations during treatment and after discontinuation of letermovir.<sup>1</sup> Tacrolimus dose adjustments may be required.<sup>1</sup><br><br>The mechanism of this interaction is likely letermovir-mediated inhibition of CYP3A4, an enzyme responsible for tacrolimus metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kropeit D, von Richter O, Stobernack HP, Rubsamen-Schaeff H, Zimmermann H. Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects [published online October 2, 2017]. <i>Clin Pharmacol Drug Dev</i>. doi: 10.1002/cpdd.388. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28967706\">[PubMed 28967706]</a></p>\n<p>2. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11747":"<p><b>Title</b> Pimozide / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of letermovir and pimozide. This combination is listed as a contraindication in letermovir prescribing information.</p> \n<p><b>Discussion</b> Although not evaluated in a clinical study, letermovir prescribing information states that coadministration of letermovir and pimozide may result in increased concentrations of pimozide and increase the risk for QTc prolongation or torsades de pointes.<sup>1</sup> Therefore, the concomitant use of letermovir and pimozide is contraindicated.<sup>1</sup><br><br>The mechanism of this interaction is likely letermovir-mediated inhibition of CYP3A4, an enzyme responsible for pimozide metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11748":"<p><b>Title</b> Ergot Derivatives / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of Ergot Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of letermovir and ergot derivatives. This combination is listed as a contraindication in letermovir prescribing information.</p>\n<div>\n <p><b>Ergot Derivatives Interacting Members</b> Dihydroergotamine, Ergoloid Mesylates, Ergonovine, Ergotamine, Methylergonovine<br><b>Exceptions</b> Bromocriptine, Cabergoline, Nicergoline, Pergolide</p>\n</div> \n<p><b>Discussion</b> Although not evaluated in a clinical study, letermovir prescribing information states that coadministration of letermovir and ergot alkaloids may result in increased concentrations of ergot alkaloids and increase the risk for ergotism.<sup>1</sup> Therefore, the concomitant use of letermovir and ergot alkaloids is contraindicated.<sup>1</sup><br><br>The mechanism of this interaction is likely letermovir-mediated inhibition of CYP3A4, an enzyme responsible for the metabolism of many ergot derivatives.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11749":"<p><b>Title</b> Pitavastatin / Letermovir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: When letermovir is coadministered with cyclosporine, the use of pitavastatin is contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of Pitavastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of letermovir and pitavastatin is not recommended. When letermovir is coadministered with cyclosporine, the use of pitavastatin is contraindicated.</p> \n<p><b>Discussion</b> The use of letermovir and pitavastatin has not been evaluated in a clinical study. However, in a pharmacokinetic study described in the letermovir prescribing information, letermovir (480 mg once daily) increased the atorvastatin (20 mg single dose) AUC and maximum serum concentration 3.3-fold and 2.2-fold, respectively.<sup>1</sup><br><br>Letermovir prescribing information states that the use of pitavastatin with letermovir is not recommended.<sup>1</sup> If letermovir is coadministered with cyclosporine, the use of pitavastatin is contraindicated.<sup>1</sup><br><br>The mechanism of this interaction is likely letermovir-mediated inhibition of OATP1B1/1B3, a transporter responsible for pitavastatin hepatic uptake. Because cyclosporine also inhibits OATP1B1, the magnitude of this interaction with pitavastatin may be greater when combined with cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11750":"<p><b>Title</b> Simvastatin / Letermovir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: When letermovir is coadministered with cyclosporine, the use of simvastatin is contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of letermovir and simvastatin is not recommended. When letermovir is coadministered with cyclosporine, the use of simvastatin is contraindicated.</p> \n<p><b>Discussion</b> The use of letermovir and simvastatin has not been evaluated in a clinical study. However, in a pharmacokinetic study described in the letermovir prescribing information, letermovir (480 mg once daily) increased the atorvastatin (20 mg single dose) AUC and maximum serum concentration 3.3-fold and 2.2-fold, respectively.<sup>1</sup><br><br>Letermovir prescribing information states that the use of simvastatin with letermovir is not recommended.<sup>1</sup> If letermovir is coadministered with cyclosporine, the use of simvastatin is contraindicated.<sup>1</sup><br><br>The mechanism of this interaction is likely letermovir-mediated inhibition of CYP3A4 and OATP1B1/1B3, an enzyme and a transporter responsible for simvastatin hepatic uptake and metabolism. Because cyclosporine also inhibits CYP3A4 and OATP1B1, the magnitude of this interaction with simvastatin may be greater when combined with cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11751":"<p><b>Title</b> Sirolimus / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased sirolimus serum concentrations and effects when combined with letermovir. Sirolimus dose reductions may be required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the letermovir prescribing information, letermovir (480 mg daily) increased the sirolimus (2 mg single dose) AUC, maximum serum concentration, and trough concentration 3.4-fold, 2.8-fold, and 3.2-fold, respectively.<sup>1</sup><br><br>The letermovir prescribing information states that because letermovir can increase sirolimus concentrations, clinicians should frequently monitor sirolimus concentrations during treatment and after discontinuation of letermovir.<sup>1</sup> Sirolimus dose adjustments may be required.<sup>1</sup><br><br>The mechanism of this interaction is likely letermovir-mediated inhibition of CYP3A4, an enzyme responsible for sirolimus metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11752":"<p><b>Title</b> Voriconazole / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Letermovir may decrease the serum concentration of Voriconazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased voriconazole serum concentrations or effects if combined with letermovir.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the letermovir prescribing information, letermovir (480 mg daily) decreased the voriconazole (200 mg twice daily) AUC, maximum serum concentration, and minimum serum concentration 44%, 39%, and 51%, respectively.<sup>1</sup><br><br>Letermovir prescribing information states that because letermovir may decrease voriconazole concentrations and effects, frequent monitoring for decreased voriconazole serum concentrations and effects should occur if these agents are combined.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but letermovir-mediated induction of CYP2C19 and/or CYP2C9, enzymes responsible for voriconazole metabolism, may contribute.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11753":"<p><b>Title</b> Warfarin / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Letermovir may decrease the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased warfarin effects (eg, decreased prothrombin time [PT]/international normalized ratio [INR], thrombosis) if combined with letermovir.</p> \n<p><b>Discussion</b> No clinical studies have evaluated the effect of letermovir on warfarin exposure. However, the letermovir prescribing information describes a pharmacokinetic study where letermovir (480 mg daily) decreased the voriconazole (200 mg twice daily) AUC, maximum serum concentration, and minimum serum concentration 44%, 39%, and 51%, respectively.<sup>1</sup> <br><br>Letermovir prescribing information states that letermovir decreased voriconazole concentrations due to induction of CYP2C19 and/or CYP2C9.<sup>1</sup> Because warfarin is also metabolized by CYP2C9, letermovir may also decrease concentrations of warfarin.<sup>1</sup> Warfarin response (ie, PT/INR) should be monitored frequently if combined with letermovir.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11754":"<p><b>Title</b> Fosphenytoin-Phenytoin / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Letermovir may decrease the serum concentration of Fosphenytoin-Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased phenytoin concentrations and effects if combined with letermovir.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> No clinical studies have evaluated the effect of letermovir on phenytoin exposure. However, the letermovir prescribing information describes a pharmacokinetic study where letermovir (480 mg daily) decreased the voriconazole (200 mg twice daily) AUC, maximum serum concentration, and minimum serum concentration 44%, 39%, and 51%, respectively.<sup>1</sup> <br><br>Letermovir prescribing information states that letermovir decreased voriconazole concentrations due to induction of CYP2C19 and/or CYP2C9.<sup>1</sup> Because phenytoin is also metabolized by CYP2C19 and CYP2C9, letermovir may also decrease concentrations of phenytoin.<sup>1</sup> Frequently monitor phenytoin concentrations if combined with letermovir.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11755":"<p><b>Title</b> AtorvaSTATin / Letermovir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: When letermovir is coadministered with cyclosporine, the use of atorvastatin is not recommended.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit the atorvastatin dose to 20 mg daily when combined with letermovir and monitor patients for increased atorvastatin toxicities (eg, myopathy, rhabdomyolysis). When letermovir is coadministered with cyclosporine, the use of atorvastatin (at any dose) is not recommended.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the letermovir prescribing information, letermovir (480 mg once daily) increased the atorvastatin (20 mg single dose) AUC and maximum serum concentration 3.3-fold and 2.2-fold, respectively.<sup>1</sup><br><br>Letermovir prescribing information states that the dose of atorvastatin should be limited to 20 mg daily when combined with letermovir.<sup>1</sup> If letermovir is coadministered with cyclosporine, the use of atorvastatin is not recommeded.<sup>1</sup><br><br>The mechanism of this interaction is likely letermovir-mediated inhibition of CYP3A4 and OATP1B1/1B3, an enzyme and transporter responsible for atorvastatin hepatic uptake and metabolism. Because cyclosporine also inhibits CYP3A4 and OATP1B1, the magnitude of this interaction with atorvastatin may be greater when combined with cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11756":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased statin effects/toxicities (eg, myopathy, rhabdomyolysis) if combined with letermovir. Statin dose reductions may be required.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the letermovir prescribing information, letermovir (480 mg once daily) increased the atorvastatin (20 mg single dose) AUC and maximum serum concentration 3.3-fold and 2.2-fold, respectively.<sup>1</sup><br><br>Letermovir prescribing information states that because letermovir may increase statin concentrations, frequent monitoring for statin toxicities (eg, myopathy, rhabdomyolysis) should occur when these agents are combined.<sup>1</sup> Statin dose reductions may be required.<sup>1</sup><br><br>The mechanism of this interaction is likely letermovir-mediated inhibition of CYP3A4 and OATP1B1/1B3, an enzyme and transporter responsible for atorvastatin hepatic uptake and metabolism. Other statins are all substrates of OATP1B1/1B3, and some are also CYP3A4 substrates.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11757":"<p><b>Title</b> Omeprazole / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Letermovir may decrease the serum concentration of Omeprazole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is typically required. If a decrease in omeprazole concentrations is highly undesirable, then increased monitoring and dose adjustment may be needed.</p> \n<p><b>Discussion</b> No clinical studies have evaluated the effect of letermovir on omeprazole exposure. However, the letermovir prescribing information describes a pharmacokinetic study where letermovir (480 mg daily) decreased the voriconazole (200 mg twice daily) AUC, maximum serum concentration, and minimum serum concentration 44%, 39%, and 51%, respectively.<sup>1</sup> <br><br>Letermovir prescribing information states that letermovir decreased voriconazole concentrations due to induction of CYP2C19 and/or CYP2C9.<sup>1</sup> Because omeprazole is also metabolized by CYP2C19, letermovir may also decrease concentrations of omeprazole.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11758":"<p><b>Title</b> Pantoprazole / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Letermovir may decrease the serum concentration of Pantoprazole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is typically required. If a decrease in pantoprazole concentrations is highly undesirable, then increased monitoring and dose adjustment may be needed.</p> \n<p><b>Discussion</b> No clinical studies have evaluated the effect of letermovir on pantoprazole exposure. However, the letermovir prescribing information describes a pharmacokinetic study where letermovir (480 mg daily) decreased the voriconazole (200 mg twice daily) AUC, maximum serum concentration, and minimum serum concentration 44%, 39%, and 51%, respectively.<sup>1</sup> <br><br>Letermovir prescribing information states that letermovir decreased voriconazole concentrations due to induction of CYP2C19 and/or CYP2C9.<sup>1</sup> Because pantoprazole is also metabolized by CYP2C19, letermovir may also decrease concentrations of pantoprazole.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11759":"<p><b>Title</b> GlyBURIDE / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of GlyBURIDE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased glyburide effects/toxicities (ie, hypoglycemia) if combined with letermovir.</p> \n<p><b>Discussion</b> Although the combination of letermovir and glyburide has not been evaluated in a clinical study, the letermovir prescribing information states that letermovir may increase glyburide concentrations.<sup>1</sup> Frequently monitor blood sugar if letermovir is combined with glyburide.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but letermovir-mediated inhibition of CYP3A4 or OATP1B1/1B3, an enzyme and transporter responsible for glyburide hepatic uptake and metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11760":"<p><b>Title</b> Rosiglitazone / Letermovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of Rosiglitazone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased rosiglitazone effects/toxicities (ie, hypoglycemia) if combined with letermovir.</p> \n<p><b>Discussion</b> Although the combination of letermovir and rosiglitazone has not been evaluated in a clinical study, the letermovir prescribing information states that letermovir may increase rosiglitazone concentrations.<sup>1</sup> Frequently monitor blood sugar if letermovir is combined with rosiglitazone.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11761":"<p><b>Title</b> Repaglinide / Letermovir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: When letermovir is coadministered with cyclosporine, the use of repaglinide is not recommended.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Letermovir may increase the serum concentration of Repaglinide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased repaglinide effects/toxicities (ie, hypoglycemia) if combined with letermovir. When letermovir is coadministered with cyclosporine, the use of repaglinide is not recommended.</p> \n<p><b>Discussion</b> Although the combination of letermovir and repaglinide has not been evaluated in a clinical study, the letermovir prescribing information states that letermovir may increase repaglinide concentrations.<sup>1</sup> Frequently monitor blood sugar if letermovir is combined with repaglinide.<sup>1</sup> When letermovir is coadministered with cyclosporine, the use of repaglinide is not recommended.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but letermovir-mediated inhibition of CYP3A4 or OATP1B1/1B3, an enzyme and a transporter responsible for repaglinide hepatic uptake and metabolism, may contribute. Because cyclosporine also inhibits CYP3A4 and OATP1B1, the magnitude of this interaction with repaglinide may be greater when combined with cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11762":"<p><b>Title</b> Letermovir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Letermovir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of letermovir and rifampin is not recommended.</p> \n<p><b>Discussion</b> Although the effect of rifampin on letermovir exposure has not been evaluated in a clinical study, the letermovir prescribing information states that because rifampin may decrease letermovir concentrations, concomitant use is not recommended.<sup>1</sup><br><br>The mechanism of this interaction has not been investigated, but rifampin-mediated induction of OATP1B1/1B3 or UGT1A1/1A3, enzymes and transporters responsible for letermovir hepatic uptake and metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prevymis (letermovir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11763":"<p><b>Title</b> Latanoprostene Bunod / Bimatoprost</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> The concomitant use of Bimatoprost and Latanoprostene Bunod may result in increased intraocular pressure. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for paradoxical increases in intraocular pressure during concomitant use. Consider avoiding this combination of therapy when possible.</p> \n<p><b>Discussion</b> Concomitant therapy with bimatoprost and latanoprost results in increased intraocular pressure in some patients being treated for primary open angle glaucoma.<sup>1,2</sup> The increase in one 18-patient study was 1.8 mmHg.<sup>1</sup> Latanoprostene bunod and latanoprost are both metabolized to the metabolite latanoprost acid, which may lead to a similar interaction with latanoprostene bunod.<sup>3</sup> The mechanism of this paradoxical effect is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doi LM, Melo LA Jr, Prata JA Jr. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: A randomised clinical trial. <i>Br J Ophthalmol</i>. 2005;89(5):547-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15834081\">[PubMed 15834081]</a></p>\n<p>2. Herndon LW, Asrani SG, Williams GH, et al. Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost. <i>Arch Ophthalmol</i>. 2002;120(6):847-849. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12049597\">[PubMed 12049597]</a></p>\n<p>3. Vyzulta (latanoprostene bunod) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11775":"<p><b>Title</b> Dasatinib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Dasatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of grapefruit juice with dasatinib.</p> \n<p><b>Discussion</b> The average dasatinib AUC and maximum serum concentration were 4.8- and 3.6-fold higher, respectively, with concurrent use of the strong CYP3A4 inhibitor ketoconazole in a study of patients with advanced solid tumors who received dasatinib 20 mg/day for 8 days together with ketoconazole 200 mg twice/day (on days 3 to 8).<sup>1</sup><br><br>According to the dasatinib prescribing information, concurrent use of dasatinib with grapefruit juice, a moderate CYP3A4 inhibitor, should be avoided.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. <i>Cancer</i>. 2010;116(6):1582-1591. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20108303\">[PubMed 20108303]</a></p>\n<p>2. Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11776":"<p><b>Title</b> Warfarin / Daclatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Daclatasvir may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients being treated with warfarin should have their INR values monitored more frequently during and immediately after treatment with daclatasvir.</p> \n<p><b>Discussion</b> According to the daclatasvir labeling INR values may change during treatment with daclatasvir-containing anti-hepatitis C regimens.<sup>1</sup> Patients being treated with warfarin should have their INR values monitored more frequently during and immediately after treatment with daclatasvir.<br><br>The specific mechanism for this potential interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11777":"<p><b>Title</b> Rosuvastatin / Obeticholic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Obeticholic Acid may increase the serum concentration of Rosuvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the obeticholic acid prescribing information, coadministration of obeticholic acid with rosuvastatin (20 mg) resulted in a 22% increase in rosuvastatin AUC and a 27% increase in rosuvastatin maximum serum concentration.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but obeticholic acid-mediated inhibition of OATP1B1/1B3, transporters responsible for rosuvastatin hepatic uptake, may contribute.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ocaliva (obeticholic acid) [prescribing information]. New York, NY: Intercept Pharmaceuticals Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11778":"<p><b>Title</b> Ciprofloxacin (Systemic) / Ataluren</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ataluren may increase the serum concentration of Ciprofloxacin (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased ciprofloxacin effects/toxicities if combined with ataluren.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ataluren product label, coadministration of ataluren and ciprofloxacin resulted in a 32% increase in ciprofloxacin exposure.<sup>1</sup><br><br>The likely mechanism of this proposed interaction is ataluren-mediated inhibition of OAT3, a transporter responsible for the active renal tubular excretion of ciprofloxacin.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Translarna (ataluren) [summary of product characteristics]. Dublin, Ireland: PTC Therapeutics International Limited; September 2017.</p>\n<p>2. Maeda K, Tian Y, Fujita T, et al. Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. <i>Eur J Pharm Sci</i>. 2014;59:94-103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24747579\">[PubMed 24747579]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11780":"<p><b>Title</b> Factor VIII Products / Emicizumab-kxwh</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Emicizumab-kxwh may enhance the thrombogenic effect of Factor VIII Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Carefully consider the potential risks and benefits of this combination. Patients receiving this combination should be monitored closely for evidence of thrombotic events, including but not limited to thrombotic microangiography (TMA), and promptly stop the factor VIII product and temporarily stop emicizumab-kxwh if there is any evidence of TMA or other thrombotic events.</p>\n<div>\n <p><b>Factor VIII Products Interacting Members</b> Antihemophilic Factor (Human), Antihemophilic Factor (Recombinant [Fc Fusion Protein]), Antihemophilic Factor (Recombinant [Pegylated]), Antihemophilic Factor (Recombinant [Porcine Sequence]), Antihemophilic Factor (Recombinant), Antihemophilic Factor/von Willebrand Factor Complex (Human)</p>\n</div> \n<p><b>Discussion</b> According to emicizumab-kxwh labeling, both thromboembolic events and TMA have been reported in some patients receiving both emicizumab-kxwh and activated prothrombin complex concentrate (aPCC) (at cumulative amounts of more than 100 U/kg/24 hrs) for 24 hours or more.<sup>1</sup> Thrombotic events have been reported in 1.1% to 5.6% of patients receiving at least one dose of aPCC, and TMA has been reported in 1.6% to 8.3% of patients receiving at least one dose of aPCC in clinical trials of emicizumab-kxwh, with improvement noted within a week of aPCC discontinuation.<br><br>Although these reports involved aPCC and not factor VIII products, the emicizumab labeling says that preclinical experiments suggest a possibility for hypercoagulability with concurrent use of recombinant factor VII or factor VIII products.<br><br>The specific mechanism for this potential interaction is not clear but likely represents additive pro-coagulant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hemlibra (emicizumab-kxwh) [prescribing information]. South San Francisco, CA: Genetech, Inc.; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11781":"<p><b>Title</b> Factor VIIa (Recombinant) / Emicizumab-kxwh</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Emicizumab-kxwh may enhance the thrombogenic effect of Factor VIIa (Recombinant). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Carefully consider the potential risks and benefits of this combination. Patients receiving this combination should be monitored closely for evidence of thrombotic events, including but not limited to thrombotic microangiography (TMA), and promptly stop factor VIIa and temporarily stop emicizumab-kxwh if there is any evidence of TMA or other thrombotic events.</p> \n<p><b>Discussion</b> According to emicizumab-kxwh labeling, both thromboembolic events and TMA have been reported in some patients receiving both emicizumab-kxwh and activated prothrombin complex concentrate (aPCC) (at cumulative amounts of more than 100 U/kg/24 hrs) for 24 hours or more.<sup>1</sup> Thrombotic events have been reported in 1.1% to 5.6% of patients receiving at least one dose of aPCC, and TMA has been reported in 1.6% to 8.3% of patients receiving at least one dose of aPCC in clinical trials of emicizumab-kxwh, with improvement noted within a week of aPCC discontinuation.<br><br>Although these reports involved aPCC and not recombinant factor VII, the emicizumab labeling says that preclinical experiments suggest a possibility for hypercoagulability with concurrent use of recombinant factor VII or factor VIII products.<br><br>The specific mechanism for this potential interaction is not clear but likely represents additive pro-coagulant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hemlibra (emicizumab-kxwh) [prescribing information]. South San Francisco, CA: Genetech, Inc.; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11782":"<p><b>Title</b> Warfarin / Grazoprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grazoprevir may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients being treated with warfarin should have their INR values monitored more frequently during and immediately after treatment with elbasvir and grazoprevir.</p> \n<p><b>Discussion</b> According to the elbasvir and grazoprevir labeling, INR values may change during treatment with elbasvir and grazoprevir-containing regimens.<sup>1</sup> Patients being treated with warfarin should have their INR values monitored more frequently during and immediately after treatment with elbasvir and grazoprevir.<br><br>The specific mechanism for this potential interaction is unclear. Similarly, the extent to which elbasvir contributes to or is responsible for this interaction is unknown. Grazoprevir is a weak CYP3A4 inhibitor, so it is the most likely to cause a pharmacokinetic interaction with warfarin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zepatier (elbasvir and grazoprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11783":"<p><b>Title</b> Warfarin / Simeprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Simeprevir may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients being treated with warfarin should have their INR values monitored more frequently during and immediately after treatment with simeprevir.</p> \n<p><b>Discussion</b> According to the simeprevir labeling, INR values may change during treatment with simeprevir-containing regimens.<sup>1</sup> Patients being treated with warfarin should have their INR values monitored more frequently during and immediately after treatment with simeprevir.<br><br>The specific mechanism for this potential interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11784":"<p><b>Title</b> Warfarin / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may diminish the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor coagulation status more closely for several weeks after initiation of ombitasvir/paritaprevir/ritonavir. Anticoagulant dose adjustment may be required. Continued close monitoring of coagulation status after discontinuation of ombitasvir/paritaprevir/ritonavir is warranted.</p> \n<p><b>Discussion</b> Although the effects of ombitasvir/paritaprevir/ritonavir on warfarin has not been evaluated in a clinical study, the effects of several other direct-acting antiviral (DAA) therapies on warfarin effects have been reported. The warfarin sensitivity index (WSI) (INR/daily dose) was an average of 23% lower following treatment for hepatitis C virus (HCV) with a DAA according to a retrospective cohort study of 271 veterans chronically maintained on warfarin.<sup>1</sup> The mean weekly warfarin dose increased by 15% from pre-DAA treatment to post-treatment. The biggest decreases in mean INR were seen within the first 3 weeks of therapy. For the 229 patients treated with a sofosbuvir-containing regimen (sofosbuvir, n=43; sofosbuvir and ledipasvir, n=168; sofosbuvir and simeprevir, n=18), the mean WSI decreased between 9.4% and 15.1%. For the 42 patients treated with an ombitasvir/paritaprevir/ritonavir and dasabuvir-containing regimen, the WSI decreased by an average of 32%. Concurrent ribavirin was used by 62% of patients, and use of ribavirin was associated with an average 16.9% additional decrease in WSI.<sup>1</sup> Twelve weeks after HCV therapy discontinuation, the WSI increased back towards baseline, but remained 10% to 12% below baseline in both groups.<sup>2</sup> <br><br>A case series describes four patients chronically maintained on warfarin who required 14% to 67% warfarin dose increases following initiation of DAA therapy consisting of ledipasvir/sofosbuvir.<sup>3</sup> Three of the four patients were receiving concurrent ribavirin. Two patients required warfarin dose reductions following completion of DAA therapy, while the other two patients did not. Similarly, a case report describes a 61-year-old male maintained on a stable acenocoumarol dose (8 mg/week for 4 months and 8 to 9.5 mg/week for the two years prior to that) for double valve replacement (target INR 2.5 to 3.5) who experienced a decrease in INR from 3 at baseline to 1.4 four weeks following initiation of DAA therapy with ombitasvir/paritaprevir/ritonavir (25/150/100 mg orally daily), dasabuvir (250 mg orally twice daily) and ribavirin (400 mg orally twice daily).<sup>4</sup> The patient required a 137.5% increase in acenocoumarol dose by end of DAA treatment and eight weeks of bridge therapy with enoxaparin. His INR increased to 4.5 two weeks following DAA therapy completion, and despite continued acenocoumarol dose adjustments, the patient experienced a spontaneous varicose vein bleed at one month following DAA completion. In another report a 58-year-old man stable on warfarin (40 mg per week, INR 2.0 to 2.5), experienced an INR of 1.2 two weeks after initiation of ombitasvir/paritaprevir/ritonavir/dasabuvir and ribavirin, and required a warfarin dose increase of 125% (90 mg per week) in order to reach a therapeutic INR.<sup>5</sup> Two weeks after completion of DAA therapy, his INR rose to 7.3. After holding warfarin for several days and decreasing the warfarin dose (42.5 mg per week), his INR stabilized in the therapeutic range.<sup>5</sup> A decrease in INR and subsequent thrombosis was also noted after initiation of sofosbuvir/velpatasvir in a warfarin treated patient.<sup>6</sup><br><br>The ombitasvir/paritaprevir/ritonavir prescribing information states that fluctuations in INR values may occur in patients receiving warfarin who are treated with ombitasvir/paritaprevir/ritonavir.<sup>7</sup> Close monitoring of INR values is recommended during treatment and during post-treatment follow-up.<sup>7</sup><br><br>The specific mechanism for this apparent interaction is unknown, as is the contribution of some of the concurrent antivirals that were present in some cases. Improvement of liver function via treatment of HCV has been suggested as at least a contributing factor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. DeCarolis DD, Westanmo AD, Chen YC, Boese AL, Walquist MA, Rector TS. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. <i>Ann Pharmacother</i>. 2016;50(11):909-917. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27465881\">[PubMed 27465881]</a></p>\n<p>2. DeCarolis DD, Chen YC, Westanmo AD. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin: twelve-week post-treatment follow-up. <i>Ann Pharmacother</i>. 2017;51(5):439-440. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28100063\">[PubMed 28100063]</a></p>\n<p>3. Britnell SR, Willets AE, Vanderman AJ, Woodard CL, Britt RB. Influence of successful chronic hepatitis C virus treatment with ledipasvir/sofosbuvir on warfarin dosing requirements in four veterans. <i>Pharmacotherapy</i>. 2016 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27716978\">[PubMed 27716978]</a></p>\n<p>4. de Lorenzo-Pinto A, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, et al. Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration. <i>J Clin Pharm Ther</i>. 2016;41(4):444-446. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27159430\">[PubMed 27159430]</a></p>\n<p>5. Puglisi GM, Smith SM, Jankovich RD, Ashby CR Jr, Jodlowski TZ. Paritaprevir/ritonavir/ombitasvir/dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report [published online November 3, 2016]. <i>J Clin Pharm Ther</i>. Doi: 10.1111/jcpt.12475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27813106\">[PubMed 27813106]</a></p>\n<p>6. Rindone JP, Mellen CK. Reduction in warfarin effect associated with sofosbuvir-velpatasvir. <i>Am J Health Syst Pharm</i>. 2017;74(17):1308-1311.</p>\n<p>7. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11785":"<p><b>Title</b> Myelosuppressive Agents / Chloramphenicol (Ophthalmic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloramphenicol (Ophthalmic) may enhance the adverse/toxic effect of Myelosuppressive Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased risk of myelosuppression (eg, neutropenia, agranulocytosis) if chloramphenicol (ophthalmic) is combined with other myelosuppressive agents.</p>\n<div>\n <p><b>Myelosuppressive Agents Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Aldesleukin, Alemtuzumab, Altretamine, Amsacrine, Arsenic Trioxide, AzaCITIDine, Belinostat, Belotecan, Bendamustine, Bevacizumab, Bexarotene (Systemic), Blinatumomab, Bortezomib, Bosutinib, Busulfan, Cabazitaxel, Capecitabine, CarBAMazepine, Carbimazole, CARBOplatin, Carfilzomib, Carmustine, Chlorambucil, Chloramphenicol (Ophthalmic), Chloramphenicol (Systemic), CISplatin, Cladribine, Clofarabine, Copanlisib, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, Daratumumab, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, Dexrazoxane, Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Edetate CALCIUM Disodium, EpiRUBicin, EriBULin, Etoposide, Etoposide Phosphate, Everolimus, Floxuridine, Flucytosine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Inotuzumab Ozogamicin, Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Ixazomib, Lenalidomide, Linezolid, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, MethIMAzole, Methotrexate, Midostaurin, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Nilotinib, Niraparib, Obinutuzumab, Olaparib, Olaratumab, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Peginterferon Alfa-2a, Peginterferon Alfa-2b, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PONATinib, Procarbazine, Propylthiouracil, Radium Ra 223 Dichloride, Radotinib, Raltitrexed, Ribociclib, RiTUXimab, RomiDEPsin, Rucaparib, Ruxolitinib, Sirolimus, SORAfenib, Streptozocin, Tacrolimus (Systemic), Tedizolid, Tegafur, Temozolomide, Temsirolimus, Teniposide, Thalidomide, Thioguanine, Thiotepa, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Trifluridine and Tipiracil, Venetoclax, VinBLAStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zidovudine, Ziv-Aflibercept (Systemic)</p>\n</div> \n<p><b>Discussion</b> Several reports have described patients who experienced severe myelosuppression with the use of chloramphenicol (ophthalmic).<sup>1,2,3</sup> Chloramphenicol (ophthalmic) product labeling states that use of chloramphenicol (ophthalmic) with other drugs associated with myelosuppression may increase the risk of these toxicities.<sup>4,5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rosenthal RL, Blackman A. Bone-marrow hypoplasia following use of chloramphenicol eye drops. <i>JAMA</i>. 1965;191:136-137. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14233236\">[PubMed 14233236]</a></p>\n<p>2. Carpenter G. Letter: Chloramphenicol eye-drops and marrow aplasia. <i>Lancet</i>. 1975;2(7929):326-327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=50539\">[PubMed 50539]</a></p>\n<p>3. Abrams SM, Degnan TJ, Vinciguerra V. Marrow aplasia following topical application of chloramphenicol eye ointment. <i>Arch Intern Med</i>. 1980;140(4):576-577. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7362398\">[PubMed 7362398]</a> </p>\n<p>4. Brolene Antibiotic Eye Drops (chloramphenicol) [summary of product characteristics]. West Malling, Kent, United Kingdom: Aventis Pharma Limited; March 2013.</p>\n<p>5. Chloramphenicol ophthalmic ointment [summary of product characteristics]. Romford, United Kingdom: Martindale Pharmaceuticals Ltd; April 2017.</p>\n<p>6. Chloramphenicol ophthalmic ointment [package leaflet]. Romford, United Kingdom: Martindale Pharmaceuticals Ltd; March 2017.</p>\n<p>7. Chloramphenicol ophthalmic solution [package leaflet]. Romford, United Kingdom: Martindale Pharmaceuticals Ltd; March 2017.</p>\n<p>8. Vistaphenicol Eye Drops (chloramphenicol) [summary of product characteristics]. Romford, United Kingdom: Martindale Pharmaceuticals Limited; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11786":"<p><b>Title</b> ClonazePAM / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of ClonazePAM. Clonazepam may also alter concentrations of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased effects of clonazepam if phenytoin is initiated/dose increased, and increased effects of clonazepam if phenytoin is discontinued/dose decreased. Monitoring of phenytoin concentration is recommended when clonazepam is co-administrated with phenytoin.</p> \n<p><b>Discussion</b> Clonazepam clearance was increased by 46% to 58% and the clonazepam half-life was decreased by 31% following pretreatment with the CYP3A inducer phenytoin in a study of 8 patients who received a single dose of clonazepam (0.03 mg/kg) after pretreatment with phenytoin 4.3 mg/kg.<sup>1</sup> The clonazepam labeling states that cytochrome P450 inducers, such as phenytoin, carbamazepine, lamotrigine, and phenobarbital induce clonazepam metabolism, causing an approximately 38% decrease in plasma clonazepam levels.<sup>2</sup><br><br>Clonazepam labeling also suggests that clonazepam has the potential to influence concentrations of phenytoin.<sup>2</sup> However, published studies are not available to further examine this interaction.<br><br>Phenytoin, a CYP3A inducer, is expected to increase the CYP3A-mediated metabolism of clonazepam of this pathway, resulting in increased clonazepam clearance and decreased clonazepam serum concentrations. Decreased effects of clonazepam would be expected. The mechanism by which clonazepam would alter phenytoin concentrations is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khoo KC, Mendels J, Rothbart M, et al. Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam. <i>Clin Pharmacol Ther</i>. 1980;28(3):368-375. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7408397\">[PubMed 7408397]</a></p>\n<p>2. Klonopin (clonazepam) [prescribing information]. San Francisco, CA: Genentech; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11787":"<p><b>Title</b> ClonazePAM / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of ClonazePAM. Clonazepam may also alter concentrations of Phenytoin (active metabolite of Fosphenytoin). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of clonazepam if phenytoin is initiated/dose increased, and increased effects of clonazepam if phenytoin is discontinued/dose decreased. Monitoring of phenytoin concentration is recommended when clonazepam is co-administrated with phenytoin.</p> \n<p><b>Discussion</b> Clonazepam clearance was increased by 46% to 58% and the clonazepam half-life was decreased by 31% following pretreatment with the CYP3A inducer phenytoin in a study of 8 patients who received a single dose of clonazepam (0.03 mg/kg) after pretreatment with phenytoin 4.3 mg/kg.<sup>1</sup> The clonazepam labeling states that cytochrome P450 inducers, such as phenytoin, carbamazepine, lamotrigine, and phenobarbital induce clonazepam metabolism, causing an approximately 38% decrease in plasma clonazepam levels.<sup>2</sup><br><br>Clonazepam labeling also suggests that clonazepam has the potential to influence concentrations of phenytoin.<sup>2</sup> However, published studies are not available to further examine this interaction.<br><br>Phenytoin, a CYP3A inducer, is expected to increase the CYP3A-mediated metabolism of clonazepam of this pathway, resulting in increased clonazepam clearance and decreased clonazepam serum concentrations. Decreased effects of clonazepam would be expected. The mechanism by which clonazepam would alter phenytoin concentrations is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khoo KC, Mendels J, Rothbart M, et al. Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam. <i>Clin Pharmacol Ther</i>. 1980;28(3):368-375. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7408397\">[PubMed 7408397]</a></p>\n<p>2. Klonopin (clonazepam) [prescribing information]. San Francisco, CA: Genentech; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11793":"<p><b>Title</b> Elbasvir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Elbasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of elbasvir and grazoprevir with strong CYP3A4 inducers is contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The effect of strong CYP3A4 inducers on elbasvir exposure has not been evaluated in a clinical study. However, in a pharmacokinetic study described in the prescribing information, the moderate inducer efavirenz (600 mg daily) decreased the elbasvir (50 mg daily) AUC, maximum serum concentration, and minimum serum concentration 53%, 45%, and 59%, respectively.<sup>1</sup><br><br>The prescribing information for elbasvir and grazoprevir lists concurrent use of strong CYP3A4 inducers as contraindicated.<sup>1</sup><br><br>The mechanism of this interaction is likely induction of CYP3A4, an enzyme responsible for elbasvir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zepatier (elbasvir and grazoprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11794":"<p><b>Title</b> Amphetamines / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Amphetamines. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for amphetamine toxicities (including serotonin syndrome) if combined with a strong CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. If serotonin syndrome occurs, discontinue amphetamine therapy.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, patients who received the CYP2D6 inhibitor bupropion (75 mg twice daily x 14 days) combined with methamphetamine (30 mg single IV dose) had a methamphetamine AUC that was 89% higher than patients who received methamphetamine alone.<sup>1</sup> In other pharmacokinetic studies, the AUC of methylenedioxymethamphetamine (MDMA; ecstasy) increased 33% when combined with bupropion,<sup>2</sup> increased 22% to 27% when combined with paroxetine,<sup>3,4</sup> and increased 16% when combined with duloxetine.<sup>5</sup> In another study, when quinidine bisulfate (250 mg single dose) was given with methoxyphenamine (60.3 mg single dose), the urinary excretion of the parent drug methoxyphenamine increased, while the urinary excretion of two metabolites decreased, suggesting the metabolism of methoxyphenamine was inhibited by quinidine.<sup>6</sup> Additionally, one case report describes a patient who experienced phentermine toxicities in the presence of fluoxetine.<sup>7</sup><br><br>Prescribing information for several amphetamine products state that amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by CYP2D6. Therefore, concomitant use with CYP2D6 inhibitors may increase exposure and lead to a greater risk for toxicities, including serotonin syndrome.<sup>8,9,10,11,12,13</sup> Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. If serotonin syndrome occurs, discontinue amphetamine therapy.<sup>8,9,10,11,12,13</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Newton TF, Roache JD, De La Garza R 2nd, et al. Safety of intravenous methamphetamine administration during treatment with bupropion. <i>Psychopharmacology (Berl)</i>. 2005;182(3):426-435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16163531\">[PubMed 16163531]</a></p>\n<p>2. Schmid Y, Rickli A, Schaffner, et al. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. <i>J Pharmacol Exp Ther</i>. 2015;353(1):102-111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25655950\">[PubMed 25655950]</a></p>\n<p>3. Farre M, Abanades S, Roset PN, et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. <i>J Pharmacol Exp Ther</i>. 2007;323(3):954-962. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17890444\">[PubMed 17890444]</a></p>\n<p>4. Segura M, Farre M, Pichini S, et al. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. <i>Clin Pharmacokinet</i>. 2005;44(6):649-660. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15910012\">[PubMed 15910012]</a></p>\n<p>5. Hysek CM, Simmler LD, Nicola VG, et al. Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. <i>PLoS One</i>. 2012;7(5):e36476. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22574166\">[PubMed 22574166]</a></p>\n<p>6. Muralidharan G, Hawes EM, McKay G, Korchinski ED, Midha KK. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. <i>Eur J Clin Pharmacol</i>. 1991;41(5):471-474. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1761076\">[PubMed 1761076]</a></p>\n<p>7. Bostwick JM, Brown TM. A toxic reaction from combining fluoxetine and phentermine. <i>J Clin Psychopharmacol</i>. 1996;16(2):189-190. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8690835\">[PubMed 8690835]</a></p>\n<p>8. Adderal XR (dextroamphetamine and amphetamine) [prescribing information]. Lexington, MA: Shire US Inc; January 2017. </p>\n<p>9. Mydayis (dextroamphetamine and amphetamine) [prescribing information]. Lexington, MA: Shire US Inc; June 2017.</p>\n<p>10. Dyanavel XR (amphetamine) [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; May 2017.</p>\n<p>11. Dexedrine (dextroamphetamine) [prescribing information]. Winchester, KY: Catalent Pharma Solutions; October 2013.</p>\n<p>12. Desoxyn (methamphetamine) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; February 2015.</p>\n<p>13. Vyvanse (lisdexamfetamine) [prescribing information]. Lexington, MA: Shire US Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11795":"<p><b>Title</b> Amphetamines / CYP2D6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for amphetamine toxicities (including serotonin syndrome) if combined with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. If serotonin syndrome occurs, discontinue amphetamine therapy.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study, patients who received the CYP2D6 inhibitor bupropion (75 mg twice daily x 14 days) combined with methamphetamine (30 mg single IV dose) had a methamphetamine AUC that was 89% higher than patients who received methamphetamine alone.<sup>1</sup> In other pharmacokinetic studies, the AUC of methylenedioxymethamphetamine (MDMA; ecstasy) increased 33% when combined with bupropion,<sup>2</sup> increased 22% to 27% when combined with paroxetine,<sup>3,4</sup> and increased 16% when combined with duloxetine.<sup>5</sup> In another study, when quinidine bisulfate (250 mg single dose) was given with methoxyphenamine (60.3 mg single dose), the urinary excretion of the parent drug methoxyphenamine increased, while the urinary excretion of two metabolites decreased, suggesting the metabolism of methoxyphenamine was inhibited by quinidine.<sup>6</sup> Additionally, one case report describes a patient who experienced phentermine toxicities in the presence of fluoxetine.<sup>7</sup><br><br>Prescribing information for several amphetamine products state that amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by CYP2D6. Therefore, concomitant use with CYP2D6 inhibitors may increase exposure and lead to a greater risk for toxicities, including serotonin syndrome.<sup>8,9,10,11,12,13</sup> Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. If serotonin syndrome occurs, discontinue amphetamine therapy.<sup>8,9,10,11,12,13</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Newton TF, Roache JD, De La Garza R 2nd, et al. Safety of intravenous methamphetamine administration during treatment with bupropion. <i>Psychopharmacology (Berl)</i>. 2005;182(3):426-435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16163531\">[PubMed 16163531]</a></p>\n<p>2. Schmid Y, Rickli A, Schaffner, et al. Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. <i>J Pharmacol Exp Ther</i>. 2015;353(1):102-111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25655950\">[PubMed 25655950]</a></p>\n<p>3. Farre M, Abanades S, Roset PN, et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. <i>J Pharmacol Exp Ther</i>. 2007;323(3):954-962. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17890444\">[PubMed 17890444]</a></p>\n<p>4. Segura M, Farre M, Pichini S, et al. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. <i>Clin Pharmacokinet</i>. 2005;44(6):649-660. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15910012\">[PubMed 15910012]</a></p>\n<p>5. Hysek CM, Simmler LD, Nicola VG, et al. Duloxetine inhibits effects of MDMA (“ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study. <i>PLoS One</i>. 2012;7(5):e36476. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22574166\">[PubMed 22574166]</a></p>\n<p>6. Muralidharan G, Hawes EM, McKay G, Korchinski ED, Midha KK. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. <i>Eur J Clin Pharmacol</i>. 1991;41(5):471-474. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1761076\">[PubMed 1761076]</a></p>\n<p>7. Bostwick JM, Brown TM. A toxic reaction from combining fluoxetine and phentermine. <i>J Clin Psychopharmacol</i>. 1996;16(2):189-190. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8690835\">[PubMed 8690835]</a></p>\n<p>8. Adderal XR (dextroamphetamine and amphetamine) [prescribing information]. Lexington, MA: Shire US Inc; January 2017. </p>\n<p>9. Mydayis (dextroamphetamine and amphetamine) [prescribing information]. Lexington, MA: Shire US Inc; June 2017.</p>\n<p>10. Dyanavel XR (amphetamine) [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; May 2017.</p>\n<p>11. Dexedrine (dextroamphetamine) [prescribing information]. Winchester, KY: Catalent Pharma Solutions; October 2013.</p>\n<p>12. Desoxyn (methamphetamine) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; February 2015.</p>\n<p>13. Vyvanse (lisdexamfetamine) [prescribing information]. Lexington, MA: Shire US Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11796":"<p><b>Title</b> Lesinurad / CYP2C9 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2C9 Inducers (Moderate) may decrease the serum concentration of Lesinurad. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased lesinurad efficacy when combined with moderate CYP2C9 inducers.</p>\n<div>\n <p><b>CYP2C9 Inducers (Moderate) Interacting Members</b> Enzalutamide, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the lesinurad prescribing information, rifampin (600 mg daily) decreased the lesinurad AUC and maximum serum concentration approximately 40% and 25%, respectively.<sup>1</sup><br><br>Lesinurad prescribing information states that because lesinurad exposure is decreased when coadministered with moderate inducers of CYP2C9, the therapeutic effect of lesinurad may be reduced.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zurampic (lesinurad) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11797":"<p><b>Title</b> Lesinurad / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Lesinurad. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the lesinurad prescribing information, rifampin (600 mg daily) decreased the lesinurad AUC and maximum serum concentration approximately 40% and 25%, respectively.<sup>1</sup><br><br>Lesinurad prescribing information states that because lesinurad exposure is decreased when coadministered with moderate inducers of CYP2C9, the therapeutic effect of lesinurad may be reduced.<sup>1</sup> Although the prescribing information lists carbamazepine as an example of a moderate CYP2C9 inducer, available clinical data suggest that the effect of carbamazepine on CYP2C9 induction is minimal.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zurampic (lesinurad) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2015.</p>\n<p>2. Hansen JM, Siersboek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. <i>Clin Pharmacol Ther</i>. 1971;12(3):539-543. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5567804\">[PubMed 5567804]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11798":"<p><b>Title</b> Nateglinide / Fosphenytoin-Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Nateglinide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> The AUC of nateglinide (60 mg single dose) was decreased 24% in 10 normal subjects when administered following a 5-day course of rifampin (600 mg daily).<sup>1</sup> The AUC of the M7 metabolite of nateglinide was decreased 19%. No changes in the hypoglycemic effects of nateglinide were noted.<sup>1</sup><br><br>Nateglinide prescribing information states that the addition of CYP inducers (rifampin, phenytoin, St. John's wort) may reduce the hypoglycemic action of nateglinide.<sup>2</sup> <br><br>The mechanism of this potential interaction has not fully been investigated, but rifampin likely induces the CYP enzymes responsible for nateglinide metabolism (CYP2C9 and 3A4) causing a decrease in nateglinide concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. <i>Br J Clin Pharmacol</i>. 2003;56(4):427-432. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12968988\">[PubMed 12968988]</a></p>\n<p>2. Starlix (nateglinide) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation: January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11799":"<p><b>Title</b> Nateglinide / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Nateglinide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of nateglinide (60 mg single dose) was decreased 24% in 10 normal subjects when administered following a 5-day course of rifampin (600 mg daily).<sup>1</sup> The AUC of the M7 metabolite of nateglinide was decreased 19%. No changes in the hypoglycemic effects of nateglinide were noted.<sup>1</sup><br><br>Nateglinide prescribing information states that the addition of CYP inducers (rifampin, phenytoin, St. John's wort) may reduce the hypoglycemic action of nateglinide.<sup>2</sup> <br><br>The mechanism of this potential interaction has not fully been investigated, but rifampin likely induces the CYP enzymes responsible for nateglinide metabolism (CYP2C9 and 3A4) causing a decrease in nateglinide concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. <i>Br J Clin Pharmacol</i>. 2003;56(4):427-432. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12968988\">[PubMed 12968988]</a></p>\n<p>2. Starlix (nateglinide) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation: January 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}